Strategies to identify candidate repurposable drugs: COVID-19 treatment as a case example

Abstract Drug repurposing is an invaluable strategy to identify new uses for existing drug therapies that overcome many of the time and financial costs associated with novel drug development. The COVID-19 pandemic has driven an unprecedented surge in the development and use of bioinformatic tools to...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ali S. Imami, Robert E. McCullumsmith, Sinead M. O’Donovan
Formato:	article
Lenguaje:	EN
Publicado:	Nature Publishing Group 2021
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
Acceso en línea:	https://doaj.org/article/f2be3084702841798028eefb4ffa0b08
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f2be3084702841798028eefb4ffa0b08
record_format	dspace
spelling	oai:doaj.org-article:f2be3084702841798028eefb4ffa0b082021-11-21T12:07:51ZStrategies to identify candidate repurposable drugs: COVID-19 treatment as a case example10.1038/s41398-021-01724-w2158-3188https://doaj.org/article/f2be3084702841798028eefb4ffa0b082021-11-01T00:00:00Zhttps://doi.org/10.1038/s41398-021-01724-whttps://doaj.org/toc/2158-3188Abstract Drug repurposing is an invaluable strategy to identify new uses for existing drug therapies that overcome many of the time and financial costs associated with novel drug development. The COVID-19 pandemic has driven an unprecedented surge in the development and use of bioinformatic tools to identify candidate repurposable drugs. Using COVID-19 as a case study, we discuss examples of machine-learning and signature-based approaches that have been adapted to rapidly identify candidate drugs. The Library of Integrated Network-based Signatures (LINCS) and Connectivity Map (CMap) are commonly used repositories and have the advantage of being amenable to use by scientists with limited bioinformatic training. Next, we discuss how these recent advances in bioinformatic drug repurposing approaches might be adapted to identify repurposable drugs for CNS disorders. As the development of novel therapies that successfully target the cause of neuropsychiatric and neurological disorders has stalled, there is a pressing need for innovative strategies to treat these complex brain disorders. Bioinformatic approaches to identify repurposable drugs provide an exciting avenue of research that offer promise for improved treatments for CNS disorders.Ali S. ImamiRobert E. McCullumsmithSinead M. O’DonovanNature Publishing GrouparticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571ENTranslational Psychiatry, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Ali S. Imami Robert E. McCullumsmith Sinead M. O’Donovan Strategies to identify candidate repurposable drugs: COVID-19 treatment as a case example
description	Abstract Drug repurposing is an invaluable strategy to identify new uses for existing drug therapies that overcome many of the time and financial costs associated with novel drug development. The COVID-19 pandemic has driven an unprecedented surge in the development and use of bioinformatic tools to identify candidate repurposable drugs. Using COVID-19 as a case study, we discuss examples of machine-learning and signature-based approaches that have been adapted to rapidly identify candidate drugs. The Library of Integrated Network-based Signatures (LINCS) and Connectivity Map (CMap) are commonly used repositories and have the advantage of being amenable to use by scientists with limited bioinformatic training. Next, we discuss how these recent advances in bioinformatic drug repurposing approaches might be adapted to identify repurposable drugs for CNS disorders. As the development of novel therapies that successfully target the cause of neuropsychiatric and neurological disorders has stalled, there is a pressing need for innovative strategies to treat these complex brain disorders. Bioinformatic approaches to identify repurposable drugs provide an exciting avenue of research that offer promise for improved treatments for CNS disorders.
format	article
author	Ali S. Imami Robert E. McCullumsmith Sinead M. O’Donovan
author_facet	Ali S. Imami Robert E. McCullumsmith Sinead M. O’Donovan
author_sort	Ali S. Imami
title	Strategies to identify candidate repurposable drugs: COVID-19 treatment as a case example
title_short	Strategies to identify candidate repurposable drugs: COVID-19 treatment as a case example
title_full	Strategies to identify candidate repurposable drugs: COVID-19 treatment as a case example
title_fullStr	Strategies to identify candidate repurposable drugs: COVID-19 treatment as a case example
title_full_unstemmed	Strategies to identify candidate repurposable drugs: COVID-19 treatment as a case example
title_sort	strategies to identify candidate repurposable drugs: covid-19 treatment as a case example
publisher	Nature Publishing Group
publishDate	2021
url	https://doaj.org/article/f2be3084702841798028eefb4ffa0b08
work_keys_str_mv	AT alisimami strategiestoidentifycandidaterepurposabledrugscovid19treatmentasacaseexample AT robertemccullumsmith strategiestoidentifycandidaterepurposabledrugscovid19treatmentasacaseexample AT sineadmodonovan strategiestoidentifycandidaterepurposabledrugscovid19treatmentasacaseexample
_version_	1718419219271385088

Strategies to identify candidate repurposable drugs: COVID-19 treatment as a case example

Ejemplares similares